Agoracom Blog Home

Posts Tagged ‘small cap’

The Critical Role of the Myelin Sheath – And How Quantum BioPharma Is Advancing the Next Frontier in MS Neuroprotection

Posted by Brittany McNabb at 3:39 PM on Wednesday, October 29th, 2025

Quantum BioPharma (NASDAQ/CSE: QNTM) is advancing a novel therapeutic approach to Multiple Sclerosis (MS) — one centered not on suppressing the immune system, but on targeting the underlying biology of demyelination, the core driver of neurodegeneration in MS. To understand why this approach matters, it’s critical to understand the role of the myelin sheath.

What Is the Myelin Sheath and Why Does It Matter?

The myelin sheath is a fatty, insulating layer that wraps around nerve cell axons — acting like the high-speed wiring system of the nervous system. It is produced by specialized glial cells: oligodendrocytes in the central nervous system (CNS) and Schwann cells in the peripheral nervous system.

Myelin’s value comes from four critical functions:

  • Insulation: Prevents electrical “leaks” in signal transmission
  • Speed: Enables saltatory conduction — signals “jump” node to node (up to 100× faster)
  • Efficiency: Reduces the energy neurons need to fire signals
  • System control: Supports cognition, movement, perception, and coordination

Without myelin, the electrical messages between brain and body slow, weaken, or misfire — leading to the symptoms widely associated with neurological disorders like MS.

What Happens in Multiple Sclerosis

In MS, the myelin sheath is progressively damaged — historically thought to be caused only by immune system attack. However, leading researchers now point to a second process at play: a degenerative component that occurs independently of immune activity.

Both pathways lead to demyelination — the loss or disruption of the myelin sheath — resulting in impaired communication between neurons.

This degradation is what produces the hallmark symptoms of MS:

  • Loss of motor coordination
  • Impaired sensory perception
  • Declining cognitive function
  • Fatigue and loss of balance

Quantum BioPharma’s Approach: Precision Neuroprotection

Unlike conventional immunosuppressive MS treatments, Lucid-MS – Quantum’s patented lead drug candidate — is not immunomodulatory.

Instead, it is designed to address demyelination at the biological level, advancing a neuroprotective strategy that could complement, rather than compete with, existing immune-focused treatments.

Lucid-MS has completed successful Phase 1 human safety trials, with no serious adverse events reported. Multiple animal studies have demonstrated significant activity relevant to demyelination biology, providing additional confidence as Quantum advances toward a Phase 2 clinical trial in people with MS.

A Thoughtful, Science-Driven Evolution in MS Treatment Strategy

The global MS treatment market is heavily concentrated on slowing immune system attack. Quantum BioPharma is moving deeper — focusing on the root mechanisms of nerve damage itself.

Its approach signals an evolution in neuroscience:

  • From suppression → to protection 
  • From reaction → to resilience 
  • From slowing disease → to targeting its biological engine 

Looking Ahead

Quantum BioPharma is positioning Lucid-MS within the growing global focus on regenerative and neuroprotective medicine. As regulatory preparation accelerates, the company continues to emphasize precision science, data integrity, and clinical depth — not speculation.

For official clinical progress updates, visit: www.QuantumBioPharma.com

Visit $QNTM HUB On AGORACOM :https://agoracom.com/ir/Quantumbiopharma

Visit $QNTM 5 Minute Research Profile On AGORACOM:https://agoracom.com/ir/Quantumbiopharma/profile

Visit $QNTM Official Verified Discussion Forum On AGORACOM:

https://agoracom.com/ir/Quantumbiopharma/forums/discussion

 

DISCLAIMER AND DISCLOSURE

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post. You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews/video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

 

Kidoz Redefines Privacy-First AdTech as Global Industry Forecast to Approach $2.5 Trillion

Posted by Brittany McNabb at 4:27 PM on Tuesday, October 28th, 2025

In a digital economy where the global AdTech market is projected to surpass USD 2.5 trillion by 2032, one company is quietly redefining what it means to advertise safely and effectively—Kidoz Inc. (TSXV: KDOZ | OTCQB: KDOZF).

A Scalable AdTech Platform for the Modern Era

Kidoz operates a global, privacy-first advertising network built for the new digital reality: one where regulations, compliance, and user protection are non-negotiable. Its proprietary Kidoz Safe Ad Network and Prado SDK enable contextual, data-free campaigns that reach audiences worldwide—spanning children, teens, and families—without sacrificing performance or compliance.

The company’s technology powers high-engagement mobile campaigns across more than 60 countries, supporting a billion-plus active gamers and app users. This scale has translated into measurable results, with Kidoz reporting record first-half 2025 revenue of USD $5.17 million, a 21% year-over-year increase, and over CAD $57 million in cumulative revenue over the past three years.

Riding the AdTech Expansion Wave

Global AdTech is growing fast—driven by AI, programmatic automation, and the surge in mobile engagement. As advertisers seek ways to comply with GDPR, COPPA, and new privacy acts worldwide, Kidoz stands out as one of the few networks fully aligned with these requirements from inception.

With AI-driven contextual targeting and a real-time campaign engine, Kidoz offers a blueprint for how digital marketing can evolve without intrusive data collection. Its model fits perfectly within an industry that’s moving toward transparency, accountability, and measurable ROI.

Innovation and Strategic Growth

Behind Kidoz’s success is a commitment to constant reinvestment. In 2025, R&D spending rose 48% year-over-year, while marketing surged 95% as the company expanded global awareness. Its platform enhancements—including the proprietary Kite IQ AI engine—enable smarter ad matching, delivering relevant experiences to users while maintaining full compliance.

These strategic investments ensure Kidoz remains competitive against giants in the USD 81 billion mobile gaming ad sector, where immersive formats and interactivity are defining the next frontier of engagement.

The Power of Privacy-First Design

Regulatory pressure has become one of the strongest tailwinds in digital advertising. Global frameworks such as GDPR and CCPA demand that companies handle user data responsibly—or face steep penalties. Kidoz’s advantage lies in the fact that its systems were purpose-built for compliance.

Its infrastructure is Google-certified, Apple-approved, and among the first to align with the EU AI Act. This foundation not only minimizes risk for advertisers but also offers a scalable path to growth in sectors where user trust is paramount.

Positioning for the Next Chapter

After years of disciplined execution, Kidoz is evolving from category pioneer to category leader. It now serves as a full-stack AdTech company, offering supply-side, demand-side, and ad-exchange solutions through a unified platform.

As global ad spend continues to shift toward mobile and contextual formats, Kidoz’s privacy-first ecosystem positions it squarely within the fastest-growing segments of the AdTech market.

Bottom line:
Kidoz Inc. represents the next generation of advertising technology—one built not on user tracking, but on intelligence, integrity, and innovation. In a USD 2.5 trillion industry racing toward automation and accountability, Kidoz stands out as a company built for the future of digital engagement.

https://www.fortunebusinessinsights.com/adtech-market-110325

 

Visit $KDOZ HUB On AGORACOM: https://agoracom.com/ir/Kidoz

Visit $KDOZ 5 Minute Research Profile On AGORACOM:https://agoracom.com/ir/Kidoz/profile

Visit $KDOZ Official Verified Discussion Forum On AGORACOM:https://agoracom.com/ir/Kidoz/forums/discussion

Watch $KDOZ Videos On AGORACOM YouTube Channel:

https://www.youtube.com/feed/library

 

DISCLAIMER AND DISCLOSURE  

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

 

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

 

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

 

NO INVESTMENT ADVICE

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

 

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

 

If you have any questions, please direct them to [email protected] 

For our full website disclaimer, please visit  https://agoracom.com/terms-and-conditions

BEYOND THE MIC: PyroGenesis CEO Commits Up To $4 Million in Fresh Financing – Here’s Why That Matters

Posted by Brittany McNabb at 5:31 PM on Tuesday, October 21st, 2025

PyroGenesis Inc. (TSX: PYR; OTCQX: PYRGF; FRA: 8PY1) isn’t your typical micro-cap industrial. The Montreal-based company has spent three decades building a portfolio of all-electric plasma technologies used in heavy industry and defense—ranging from plasma torches and waste destruction systems to titanium powders for additive manufacturing. 

In a new interview, President & CEO P. Peter Pascali detailed a financing move that normally wouldn’t warrant headlines: a non-brokered private placement. What elevates this one is simple—he plans to personally invest roughly up to $4 million. The conversation offers investors a clear window into the “why,” the mechanics of the raise, and how management is positioning PyroGenesis against choppy macro currents.

The Raise, Explained: Two Unit Structures, One Message

The placement is split into two unit groups—a structure driven by TSX rules that limit insider participation over a six-month window:

  • Unit Group A (CEO tranche):
    ~6.67 million units at $0.63 each; each unit includes one common share and one warrant exercisable at $0.28 for 48 months.
    Intent: Mr. Pascali expects to subscribe for most or all of this group.
  • Unit Group B (general tranche):
    4 million units at $0.20 each; each unit includes one common share and one warrant exercisable at $0.40 for 24 months.

Both groups may close in up to three tranches and carry the standard four-months-and-a-day hold.

Investor takeaway: the CEO is committing significant personal capital on terms that require future execution to pay off.

Why Now? A Candid View From the Corner Office

Pascali’s rationale blends conviction with pragmatism:

  • Alignment by design. He is already the largest shareholder, and has invested more than $13 million in recent years (and has provided short-term loans when needed
  • Execution. Management points to a previously disclosed ~$50–51 million backlog and named collaborations in Europe (Constellium, Norsk Hydro, GE). European customers reassessed broader plans as their economies experienced volatility at different times, but PyroGenesis continued to innovate, sign new contracts, and prepare for the eventual start of the projects associated to these major collaborations.
  • Geographic momentum. The **Middle East—particularly Saudi Arabia—**is emerging as a growth lane, with leadership pushing industrial modernization, localization, and advanced manufacturing (including 3D printing). PyroGenesis already manufactures key systems in the U.S. when needed, which can blunt tariff effects and streamline deliveries.

Strategy in Plain English: What PyroGenesis Actually Does

PyroGenesis develops and commercializes ultra-high-temperature, all-electric plasma technologies that help heavy industry:

  • Replace fossil-fuel burners with plasma torches in high-temp industrial processes.
  • Convert problematic waste into usable by-products or safely destroy it.
  • Produce advanced materials, including critical minerals such as titanium powders for 3D printing.

These are factory-floor solutions, not lab concepts. The company’s systems have been adopted by conservative, blue-chip operators precisely because they target efficiency, cost, reliability, emissions, and throughput—the metrics that matter to plant managers and CFOs alike.

What’s Different About This Moment

Capital discipline and access. In a market where many micro-caps face higher rates, sticky inflation, and slower funding, PyroGenesis can partially self-fund growth through insider participation while it executes on signed work.

Operational resilience. The company builds in both Canada and the U.S. to satisfy customer or policy requirements and actively monitors supplier health to reduce tariff and supply-chain risk.

Selective innovation. The team prioritizes projects with repeat-order potential and credible paths to scale—“no Hail Marys,” as Pascali puts it. That philosophy underpins a strategy designed for recurring orders rather than one-off wins.

Risks, Put Straight

No leader sugarcoated the macro picture. The CEO flagged:

  • Market volatility that seemingly changes weekly.
  • Tariffs that impact customers’ bottom lines, even when PyroGenesis itself can manufacture locally and in the U.S. to stay relatively free of tariff impact.
  • Working-capital timing, especially where large industrial clients phase payments.

The counterweight: a 34 year history of navigating shocks, a diversified customer base (mostly in Europe and the Middle East), strong backlog, and the CEO’s capital at work.

Why Investors Are Paying Attention

For current and prospective shareholders, several points stand out:

  • Skin in the game: An up to ~$4 million personal commitment from the CEO—on tougher terms
  • Industrial credibility: Deployed systems in demanding environments (on land and at sea), across 22 countries, and long-term relationships with leading metals manufacturers.
  • Path to scale: A backlog that underwrites near-term activity, plus growth vectors in Europe, North America, and the Gulf.
  • Constant Innovation: as an example, the company has increased the power of its plasma torches 20X in 5 years, from 900kW to 20MW, while improving efficiency – widening the addressable market at both the higher power (top) and lower cost (bottom) ends.

The Bottom Line

PyroGenesis is not a concept story; it’s a commercialization story. The private placement—especially the CEO’s tranche—won’t solve every macro headwind, but it does two important things: it fortifies working capital without bank leverage, and it tightens alignment between leadership and shareholders at a pivotal stage.

As Pascali put it, the decision is ultimately judged by execution. With a $50M+ backlog, marquee industrial customers, and growing demand for electrified, cleaner high-heat processes across many different heavy industries, the company has tangible levers to pull. In a market that rewards focus and resilience, PyroGenesis is making a case that it has both.

https://agoracom.com/ir/PyroGenesisCanada/forums/discussion/topics/813951-VIDEO—PyroGenesis-CEO-Invests-Big%3A-%244-Million-of-His-Own-Money/messages/2446072

 

This Small Cap AI Company Is Building Toward the Deloitte of the AI + Web3 Era

Posted by Brittany McNabb at 3:56 PM on Thursday, October 16th, 2025

A RARE COMEBACK STORY

In a market where most halted small-cap companies never return, Fobi AI has defied expectations. Under a cease-trade order since November 2024, the company didn’t fade into obscurity—the company reported nearly $3 million in 2024 revenue, including approximately $2.2 million from the sale of its German subsidiary. As CEO Rob Anson put it: “Most companies would have folded under these circumstances. We fought through every obstacle legal, financial, and market-driven and we’re coming back stronger than ever.”

FROM SURVIVAL TO STRATEGY

Fobi turned a year of constraint into a year of transformation: Consolidated operations with an annual run rate under $1.3M, enabling scale with fewer than 10 employees Redirected capital from the Passcreator sale into next-gen AI-powered wallet platforms Positioned itself as a lean, execution-first company with live products in the market

ENTERING A MULTI-BILLION-DOLLAR ARENA

The company isn’t merely returning, it’s relaunching with sharper focus. Fobi’s ambition is to become the “Deloitte of the AI + Web3 era,” offering enterprises not just strategy, but real-time implementation through integrated wallets, identity verification, and automation platforms. With applications across stadiums, airports, healthcare, and finance, the addressable market spans multiple sectors.

WHY THIS MATTERS FOR INVESTORS

Clear Market Fit: Enterprise clients need AI integration that traditional consultants can’t deliver Execution Edge: Products are live, scalable, and already generating client interest

LOOKING AHEAD

Fobi’s comeback is more than a return to trading—it is a reset. With tangible revenues, streamlined operations, and a future-focused product suite, the company is positioning itself as one of the rare small-cap survivors with the potential to thrive in the AI and Web3 economy. For investors, this represents a strategic reset rather than just a recovery, as the company builds toward its next growth phase.

This Small Cap Company’s CEO Is Investing Another $4,000,000 of His Own Money

Posted by Brittany McNabb at 3:53 PM on Thursday, October 16th, 2025

LEADERSHIP WITH SKIN IN THE GAME

In an environment where CEOs of public companies are often urged to “show leadership” by investing personally, PyroGenesis (TSX: PYR | OTCQX: PYRGF) is setting a rare benchmark for a small or micro-cap company. In this interview, CEO Peter Pascali discusses why he is committing an additional $4 million of his own capital to support PyroGenesis — the leader in innovating for ultra-high temperature processes and engineering, and a technology provider to heavy industry & defense.

This isn’t a symbolic gesture. It’s the latest installment in a personal commitment that now exceeds $19 million invested into the company, underscoring both confidence and alignment with shareholders.

CUSTOMER VALIDATION AT THE HIGHEST LEVEL

PyroGenesis’ technologies aren’t theoretical; they are deployed in some of the world’s most demanding environments. For example, its plasma arc waste destruction systems have been installed on two U.S. Navy aircraft carriers, the USS Gerald R. Ford and USS John F. Kennedy, with two more systems to follow as the additional ships’ construction is completed — a testament to the company’s ability to pass the most stringent procurement tests.

Major industrial players such as Norsk Hydro, Constellium, and GE Vernova in Europe have publicly announced projects or relationships with PyroGenesis, signaling acceptance by highly selective partners.

“I’ve seen hundreds of companies, maybe thousands, in my career,” says Pascali. “I’ve not seen one like PyroGenesis. The technology is thrilling, the adoption is real, and even in today’s market we’ve built a backlog of signed contracts around $50 million.”

STRATEGIC POSITIONING IN A VARIETY OF MARKETS

European customers aside, PyroGenesis is building momentum in the Middle East — particularly Saudi Arabia — where national leaders are investing heavily to diversify away from oil. From advanced manufacturing, to aluminum production, to 3D printing, PyroGenesis’ portfolio aligns with the region’s push to onshore high-tech production and accelerate industrial transformation.

This geographic diversification also helps buffer against economic or supply chain challenges that may face various regions, giving PyroGenesis flexibility to manufacture in North America or abroad depending on customer needs.

OUTLOOK: A UNIQUE SMALL-CAP OPPORTUNITY

PyroGenesis is navigating the same capital and interest-rate headwinds facing many small and micro-caps — but with a critical difference: a CEO who repeatedly steps up as the largest investor, a growing range of validated technologies, and a diversified global market strategy. For investors seeking a small cap company with real technologies, real and prominent customers, and leadership fully aligned with shareholder interests, this interview offers an unfiltered look at a rare story.

Watch the full discussion to see why PyroGenesis’ CEO believes the company continues to be well positioned — and why he’s backing that belief with millions of his own dollars.

 

VIDEO REPLAY -: AGORACOM Tokenized Financing Webcast

Posted by AGORACOM-JC at 2:52 PM on Wednesday, September 24th, 2025

Last month on August 12th, AGORACOM made history once again by holding our first ever Real World Asset Tokenized Financing Webcast, in partnership with BlockRidge, our Dubai-based RWA global partners – and over 200+ small cap executives.

To say the webcast went exceedingly well would be an understatement, considering the Q&A session went longer than the webcast itself. For those of you who were on the webcast, you again have our deepest thanks and appreciation for taking the time to watch and participate with such enthusiasm.

Given the timing of the webcast, many of you were on vacation and sent both your regrets for not being able to participate, as well as, requests for the replay video.  Many attendees also asked for the replay to share with members of their teams who could not attend.

Ask and you shall receive because the full replay is now available on demand.  Simply click on the image below to either watch the video … or even listen to it while driving or walking.

THE PARADIGM SHIFT HAS STARTED – MORE WEBCASTS ON THE WAY

Given the multiple layers of RWA tokenization and requests by many of you over the past month, we’re happy to announce that AGORACOM will be hosting further webcasts to inform and educate all of you on how to participate in the paradigm shifting power of tokenized financing.

As an example of just how fast this paradigm shift is moving, the following major stories broke over just the last 45 days:

What does this mean for small cap companies?  Issuers who want to use AGORACOM and tokenization as a way to raise money, access global investor bases and escape the grip of predatory traditional financing … are finally going to get their chance.  .

FINANCING DISCUSSIONS HAVE ALREADY STARTED – $350 MILLION +

Discussions are already under way with multiple companies from traditional gold to rural telecom networks representing just under $400M in potential financing.  If you need to raise a minimum of $20,000,000 against a current real world asset that is set to achieve commercialization within 24 months, then please reply to this message.

GET YOUR POPCORN READY AND WATCH OUR VIDEO

In the meantime for those of you who are just starting your RWA journey, please enjoy the webcast and we look forward to talking soon.  This isn’t theory. It’s a groundbreaking shift designed to rewrite the rules of capital raising.

AGORACOM is proud to be leading this transformation and we want you to be part of it. Don’t miss the chance to see how tokenization is reshaping the future of small cap markets.

✅ Solutions That Matter: RWA Tokenization tackles predatory terms & naked short selling
✅ Global Access: Compliant RWA infrastructure + blockchain technology opens doors to investors worldwide

Watch the Replay Now.

Magma Silver Targets District-Scale Discovery Thanks To Historical Work By Majors

Posted by Brittany McNabb at 2:42 PM on Wednesday, September 24th, 2025

“This is the easiest mining project I’ve seen in 40 years — on or near surface, high recovery rates, and significant upside the majors left untapped.” CEO Stephen Barley

A LEGACY OF MAJOR INVESTMENT

With gold at record highs and silver at a 14-year peak, Magma Silver Corp. (CSE: MGMA / OTCQB: MAGMF) is advancing a flagship Peruvian project that has already seen $14.5 million in exploration by majors including Newmont, AngloGold, and Bear Creek. Today, Magma is applying modern geological modeling to unlock the full value of what those majors left behind.

WHY THIS PROJECT MATTERS

  • DISTRICT-SCALE SYSTEM: The property spans 40 km², including an 8 km by 2 km anomalous zone with multiple gold and silver targets.

  • CLEAN SILVER ADVANTAGE: Unlike many deposits labeled “silver equivalent,” Magma’s system has pure silver with no contaminant metals — a rare and attractive characteristic.

  • JUMPSTART ON RESOURCE: With access to Newmont’s 65 drill holes and data, Magma can fast-track toward a compliant resource.
  • PERU SILVER RECORD:  Peru is one of the world’s top jurisdictions for silver and gold exploration as the 3rd largest silver producer globally – and a top 15 mining jurisdiction worldwide.

DRILLING AND RESULTS WILL BEGIN TO FLOW IN 2025

Magma’s Phase 1 sampling confirmed high-grade results, including 14 g/t gold and 311 g/t silver in surface samples. Drilling begins mid-November with six holes planned, and results expected before year-end — setting the stage for steady news flow through 2026.

RWA TOKENIZATION IS ON THE TABLE

The company is exploring real asset tokenization to monetize gold in the ground while minimizing dilution — an innovative financing path rarely seen at this stage. Longer term, Magma sees precedent in the Alamo Dorado Project, a discovery that sold for over $100 million when silver was just $5/oz.

THE INVESTMENT CASE

At a market cap of just ~$6M CAD, Magma Silver offers investors:

  • A project already advanced by global majors

  • Proven high-grade sampling results consistent with majors

  • District-scale exploration potential

  • And a management team with a track record of successful discoveries and financings.

With drilling underway and catalysts imminent, Magma Silver is positioning itself as one of Peru’s next major gold-silver stories at a time when the sector is gaining global momentum.

Renforth Resources Positioned at the Crossroads of Gold’s Bull Market and Critical Minerals Boom

Posted by Brittany McNabb at 4:20 PM on Monday, August 18th, 2025

Industry Outlook and Renforth Resources Trajectory

Gold’s three historic bull markets—1979, 2011, and today’s surge in 2025—showcase the evolving role of the metal as both hedge and store of value. Unlike past spikes driven by short-term crises, today’s rally is grounded in structural shifts: persistent fiscal deficits, reserve diversification, and renewed geopolitical uncertainty. With gold now trading above $3,300 per ounce, projects that are accessible, near-surface, and located in stable jurisdictions are drawing heightened attention.

 

Renforth Resources, advancing its Parbec Gold Deposit and Malartic Metals Package in Quebec, is strategically aligned with these macro dynamics. Its assets combine proven ounces of gold with critical mineral potential, positioning the company at the intersection of two growth narratives.

Voices of Authority

Industry observers note the distinct nature of today’s gold cycle. Unlike the parabolic surge of 1979 or the crisis-driven peak of 2011, the 2025 market has built strength over years of consolidation. Analysts highlight that central banks, institutional investors, and governments are underpinning the rally with sustained demand. This long-term structural bid provides a foundation for companies like Renforth that can deliver scalable resources in politically secure environments.

Renforth Resources Highlights

Renforth’s trajectory can be summarized through its milestones:

  • Flagship Asset: The Parbec Gold Deposit, with a confirmed 363,000 ounces, 87% contained in an optimized open-pit shell, directly adjacent to Agnico Eagle’s Canadian Malartic Mine. 
  • Location Advantage: All-season road and ramp access, as well as close proximity to processing infrastructure, reduce barriers to development. 
  • Advancement: Ongoing exploration at Parbec and critical metals properties, including Victoria, Lalonde, and Fouillac, supports both gold and multi-metal growth strategies. 
  • Scale Potential: The Malartic Metals Package spans ~300 km², already confirming nickel, copper, and zinc occurrences with road access. 
  • High-Value Strategy: With future bulk sampling permitted at Parbec and maiden resource modeling underway at Victoria, Renforth is creating optionality across both gold and critical minerals. 

Real-world Relevance

For businesses and investors, Renforth’s assets represent more than geological data. The company’s work translates into secure, strategically located resources that align with global priorities: gold as a hedge against fiscal uncertainty and critical minerals as building blocks of electrification and energy transition. The company’s ability to operate near established infrastructure in Quebec—one of the world’s most respected mining jurisdictions—adds further real-world value by minimizing logistical challenges and development risk.

Looking Ahead with Renforth Resources

The parallels between today’s gold market and prior bull cycles are clear, but the current cycle has broader foundations. As global institutions embed gold more deeply into their strategic reserves, and as demand for critical minerals accelerates, Renforth is positioned to benefit from both sides of this structural shift. The company’s near-term milestones—Parbec surface stripping, bulk sampling, and Victoria’s maiden resource estimate—reflect its focus on disciplined progress and operational leverage within the broader bull market.

Conclusion

Gold’s role in 2025 is larger and more enduring than in prior bull markets. Against this backdrop, Renforth Resources offers a rare combination: a growing gold deposit adjacent to a major producer and a critical metals package with regional scale. Together, these assets position the company as a relevant participant in Quebec’s mining future, aligned with the industry’s most powerful macro forces.

Source: https://x.com/KitcoNewsNOW/status/1957105617341997265

 

YOUR NEXT STEPS 

Visit $RFR HUB On AGORACOM:https://agoracom.com/ir/RenforthResources

Visit $RFR 5 Minute Research Profile On AGORACOM:https://agoracom.com/ir/RenforthResources/profile

Visit $RFR Official Verified Discussion Forum On AGORACOM:https://agoracom.com/ir/RenforthResources/forums/discussion

DISCLAIMER AND DISCLOSURE  

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

 

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

 

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

 

NO INVESTMENT ADVICE

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

 

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

 

If you have any questions, please direct them to [email protected] 

For our full website disclaimer, please visit https://agoracom.com/terms-and-conditions

Quantum BioPharma’s Year of Execution: Clinical Momentum, Platform Progress, and a Stronger Balance Sheet

Posted by Brittany McNabb at 4:19 PM on Monday, August 18th, 2025

Advancing a Novel Approach to Multiple Sclerosis

Quantum BioPharma Ltd. (NASDAQ: QNTM; CSE: QNTM) is advancing therapies for challenging neurological and related conditions with a lead focus on multiple sclerosis (MS). Its flagship program, Lucid-MS (Lucid-21-302), is a patented, non-immunomodulatory compound designed to protect myelin—the insulating sheath around nerve fibers that is damaged in MS. Unlike many approved MS drugs that primarily suppress immune activity, Lucid-MS targets neuroprotection and myelin integrity, a differentiated strategy supported by preclinical data showing prevention of demyelination and reversal of paralysis.

From First-in-Human to Phase 2 Readiness

The program progressed through first-in-human testing with a Phase 1 multiple-ascending-dose (MAD) trial in healthy adults. The Clinical Study Report (CSR) concluded no safety or tolerability concerns following consecutive daily dosing—an essential milestone for opening the path to patient studies. In parallel, Quantum has signed an agreement with a leading CDMO to manufacture an oral formulation of Lucid-MS as the drug product for its planned Phase 2 clinical trial. The company has also begun preparing key components for an FDA Investigational New Drug (IND) application and submitted Lucid-MS to the UK’s ILAP Passport program, a pathway intended to accelerate access to promising medicines.

Measuring What Matters: Imaging Collaboration with MGH

A frequent obstacle in neuroprotective drug development is proving biological effect. To address this, Quantum is collaborating with Massachusetts General Hospital (MGH) scientists on imaging approaches to monitor myelin integrity. On August 5, 2025, MGH investigators published data in the European Journal of Nuclear Medicine and Molecular Imaging showing that PET tracer [18F]3F4AP exhibited strong brain-imaging properties and could detect differences across MS lesions not visible on conventional MRI. This tracer—developed at MGH and evaluated in healthy controls and people with MS—may serve as a biomarker to track demyelination and treatment response, potentially enhancing the precision of future Lucid-MS efficacy studies.

Pipeline Breadth: Phase 2 Ethics Approval for FSD202 in Australia

Beyond MS, Quantum’s pipeline includes FSD202, which targets nociplastic pain associated with idiopathic Mast Cell Activation Syndrome (MCAS)—a difficult-to-treat presentation of chronic, widespread musculoskeletal pain. In 2025, the company received Human Ethics Review Committee (HERC) approval in Australia for a Phase 2 randomized, double-blind, placebo-controlled trial designed to evaluate safety and efficacy in this population.

Spinout Progress Without Shareholder Dilution

Quantum also created value by spinning out the consumer OTC version of its alcohol-related wellness asset unbuzzd™ to Unbuzzd Wellness Inc. Quantum retains an equity stake (approximately 20% as of mid-2025) and royalty rights of 7% of sales until $250 million is reached, then 3% in perpetuity. In 2025, Unbuzzd launched a Reg D 506(c) capital raise of up to US$5 million to fund growth and a potential go-public path. The company noted this financing does not dilute Quantum BioPharma shareholders. Unbuzzd’s U.S. commercialization continues, with additional regulatory steps underway for Canada.

Strengthening the Balance Sheet

Operational progress has been matched by financial housekeeping. For the quarter ended June 30, 2025, Quantum reported:

  • Current assets of US$10.3 million (up from US$9.9 million at March 31, 2025) and total assets of US$15.3 million (up from US$14.9 million).
  • All debentures converted to equity, removing that liability; previously recorded warrant liability (a non-cash item) was eliminated as all outstanding warrants were exercised by the date of filing.
  • Receipt of a US$2.35 million settlement related to prior management litigation; the Sports Coat litigation loan was fully repaid with full release received.
  • Treasury diversification that includes approximately US$5.5 million of Bitcoin and other cryptocurrencies, with over US$500,000 in realized and unrealized gains as of filing.
  • Management indicated sufficient cash on hand to maintain basic operations beyond March 2027.

During Q2 2025, the share price rose from US$7.71 (March 31) to US$20.25 (June 30), reflecting a period of notable execution across clinical, operational, and financial fronts.

Outlook

Quantum BioPharma enters the next phase with a de-risked safety profile for its lead MS candidate, manufacturing in place for an oral Phase 2 program, and an imaging collaboration that could sharpen efficacy readouts. The company is also advancing FSD202 into a Phase 2 study in Australia and maintaining non-dilutive exposure to a commercializing consumer asset via Unbuzzd. Combined with a cleaner balance sheet and extended cash runway, the setup positions Quantum to pursue upcoming clinical and corporate milestones with focus and flexibility.

All program descriptions reflect company disclosures, published study findings from MGH collaborators, and the most recent financial updates provided by Quantum BioPharma in 2025.

 

Visit $QNTM HUB On AGORACOM : https://agoracom.com/ir/Quantumbiopharma

Visit $QNTM 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/Quantumbiopharma/profile

Visit $QNTM Official Verified Discussion Forum On AGORACOM:

https://agoracom.com/ir/Quantumbiopharma/forums/discussion

DISCLAIMER AND DISCLOSURE 

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post. You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000. 

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

HPQ Silicon Fast-Tracks Breakthrough Battery Tech From Lab to Production

Posted by Alavaro Coronel at 10:27 AM on Friday, August 15th, 2025

FROM LAB SUCCESS TO MARKET-READY PRODUCT

HPQ Silicon $HPQ / $HPQFF has moved from prototype to production in record time, delivering its first commercial-scale silicon-anode battery cells — a milestone that positions the company at the forefront of a ~$16B market for mobility, electronics, and energy storage.

The company began manufacturing HPQ ENDURA+ 18650 and 21700 cells, delivering 4,000 mAh and 6,000 mAh capacity with lifespans approaching 1,000 cycles — performance that CEO Bernard Tourillon says is “unheard of” in commercially sized batteries. Independent third-party validation confirmed the results first achieved at the lab scale are now replicable in industrial production.

GLOBAL INTEREST AND STRATEGIC POSITIONING

  • Inquiries from Asia, Europe, and North America including power tool, e-bike, drone, and military suppliers
  • Partnership discussions underway with industry leaders, including graphite producers seeking to enhance their products with HPQ’s silicon-anode material
  • Ability to integrate into existing battery manufacturing lines without costly retooling

“We continue to receive inquiries from global potential customers and are engaging in technical discussions with leading industry players… With production now underway, we anticipate an acceleration of partnership opportunities as soon as we start delivering.” — Bernard Tourillon, CEO, HPQ Silicon

SCALABLE GROWTH POTENTIAL

The company estimates that a 50-ton annual production facility for its proprietary silicon-anode material — an investment of $5–$7 million — could supply up to 25–30 million batteries. With North American exclusivity via its partnership with Novacium, HPQ is positioned to scale quickly as orders come in.

WHY INVESTORS ARE WATCHING

HPQ has compressed the typical multi-year commercialization cycle into under 18 months, leapfrogging the pilot phase and moving directly to commercial manufacturing. By demonstrating its technology in market-ready cells, HPQ aims to convert competitors into customers, accelerate adoption, and secure a foothold in high-value battery segments.

Bottom line: HPQ Silicon is no longer just developing — it’s delivering. With global attention, validated performance, and a clear path to scale, the company is poised to become a key supplier in the next generation of high-performance batteries.